Kathelijne Kraal

Dr. Kathelijne Kraal


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
KKKathelijne Kraal
Kathelijne Kraal
GBG.M. Bleeker
G.M. Bleeker
BEB.L.F. van Eck-Smit
B.L.F. van Eck-Smit
NEN.K.A. van Eijkelenburg
N.K.A. van Eijkelenburg
FBF. Berthold
F. Berthold
GTG.A.M. Tytgat
G.A.M. Tytgat

17 November 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
MTMichelle L. Tas
Michelle L. Tas
MNMichelle Nagtegaal
Michelle Nagtegaal
KKKathelijne Kraal
Kathelijne Kraal
GTGodelieve A.M. Tytgat
Godelieve A.M. Tytgat
NANico G.G.M. Abeling
Nico G.G.M. Abeling
MNMax M. Van Noesel
Max M. Van Noesel
Background: The clinical course of neuroblastoma stage 4S or MS is characterized by a high rate of spontaneous tumor regression and favorable outcome. However, the clinical course and rate of the regression are poorly understood.Methods: A retrospective cohort study was performed, including all patients with stage 4S neuroblastoma without MYCN amplification, from two Dutch centers between 1972 and 2012. We investigated the clinical characteristics, the biochemical activity reflected in urinary catecholamine excretion, and radiological imaging to describe the kinetics of tumor regression, therapy response and outcome.Results: The cohort of 31 patients reached a 10‐year overall survival of 84% ± 7% (median follow‐up 16 years; range, 3.3‐39). During the regressive phase, liver size normalized in 91% of the patients and catecholamine excretion in 83%, both after a median of two months (liver size: range, 0‐131; catecholamines: range, 0‐158). The primary tumors completely regressed in 69% after 13 months (range, 6‐73), and the liver architecture normalized in 52% after 15 months (range, 5‐131). Antitumor treatment was given in 52% of the patients. Interestingly, regression rates were similar for treated and untreated patients. Four of seven patients < 4 weeks old died of rapid liver expansion and organ compression. Three patients progressed to stage 4, 3 to 13 months after diagnosis; all had persistently elevated catecholamines.Conclusion: Patients < 4 weeks old with neuroblastoma stage 4S are at risk of fatal outcome caused by progression of liver metastases. In other patients, tumor regression is characterized by a rapid biochemical normalization that precedes radiological regression.

2 February 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
KKKathelijne Kraal
Kathelijne Kraal
TBThomas Blom
Thomas Blom
MNMax van Noesel
Max van Noesel
LKLeontien Kremer
Leontien Kremer
HCHuib Caron
Huib Caron
HPHeleen van der Pal
Heleen van der Pal

26 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CSCelina Szanto
Celina Szanto
ACAnnelisa Cornel
Annelisa Cornel
STSara M. Tamminga
Sara M. Tamminga
EDEveline M. Delemarre
Eveline M. Delemarre
CKCoco de Koning
Coco de Koning
SNStefan Nierkens
Stefan Nierkens
Despite intensive treatment, including consolidation immunotherapy (IT), prognosis of high-risk neuroblastoma (HR-NBL) is poor. Immune status of patients over the course of treatment, and thus immunological features potentially explaining therapy efficacy, are largely unknown. In this study, the dynamics of immune cell subsets and their function were explored in 25 HR-NBL patients at diagnosis, during induction chemotherapy, before high-dose chemotherapy, and during IT. The dynamics of immune cells varied largely between patients. IL-2- and GM-CSF-containing IT cycles resulted in significant expansion of effector cells (NK-cells in IL-2 cycles, neutrophils and monocytes in GM-CSF cycles). Nonetheless, the cytotoxic phenotype of NK-cells was majorly disturbed at the start of IT, and both IL-2 and GM-CSF IT cycles induced preferential expansion of suppressive regulatory T-cells. Interestingly, proliferative capacity of purified patient T-cells was impaired at diagnosis as well as during therapy. This study indicates the presence of both immune-enhancing as well as regulatory responses in HR-NBL patients during (immuno)therapy. Especially the double-edged effects observed in IL-2-containing IT cycles are interesting, as this potentially explains the absence of clinical benefit of IL-2 addition to IT cycles. This suggests that there is a need to combine anti-GD2 with more specific immune-enhancing strategies to improve IT outcome in HR-NBL.

21 April 2017 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
KKKathelijne Kraal
Kathelijne Kraal
EDElvira C van Dalen
Elvira C van Dalen
GTGodelieve Am Tytgat
Godelieve Am Tytgat
BEBerthe Lf Van Eck-Smit
Berthe Lf Van Eck-Smit

30 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MTMichelle L. Tas
Michelle L. Tas
LDLisa Dootjes
Lisa Dootjes
MFMarta Fiocco
Marta Fiocco
Ronald de KrijgerRonald de Krijger
Ronald de Krijger
MDMiranda Dierselhuis
Miranda Dierselhuis
MNMax M. Van Noesel
Max M. Van Noesel
Background: Anti-GD2 based immunotherapy has improved overall (OS) and event free survival (EFS) for high-risk neuroblastoma (HR-NBL) patients. Here, we evaluate the long-term efficacy of anti-GD2 immunotherapy in combination with isotretinoin, GM-CSF, and IL-2. Methods: Dutch HR-NBL patients treated with immunotherapy according to the COG-ANBL0032 protocol (n = 47) were included and compared to historical controls (n = 37) treated with single-agent isotretinoin maintenance therapy. Survival time was calculated from start of the maintenance therapy. Results: The study and control group were similar concerning baseline characteristics. In the complete cohort, 5 year OS was 64 ± 7% and 49 ± 8% for the immunotherapy group and the control group, respectively (p = 0.16). Five year EFS was 57 ± 7% and 41 ± 8%, respectively (p = 0.16). In the subgroup of patients ≥ 18 months, 5-yr OS was 63 ± 8% and 39 ± 9, respectively (p = 0.04) and EFS 54 ± 8% and 29 ± 8%, respectively (p = 0.05). Landmark analysis for EFS with landmark point at 6 months after start of maintenance suggests a larger effect on the prevention of late than early events. Conclusions: This study is the first to confirm the results of the COG-ANBL0032 study in a cohort treated with a different induction regimen. Anti-GD2 immunotherapy prevents late events, most significantly in patients older than 18 months of age at diagnosis.